Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Schott Pharma AG KGaA's gross profit for the
three
months ended in Jun. 2026 was $100 Mil. Schott Pharma AG KGaA's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $369 Mil.
Schott Pharma AG KGaA (OTCPK:SHTPY) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Schott Pharma AG KGaA had a gross margin of 30.66% for the quarter that ended in Jun. 2026 => Competition eroding margins
Schott Pharma AG KGaA Gross Profit Related Terms
Schott Pharma AG KGaA Gross Profit Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Gross Profit distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $369 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Schott Pharma AG KGaA (SHTPY) has a Gross Profit of $369 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Schott Pharma AG KGaA and its competitors.
Is Schott Pharma AG KGaA's Gross Profit too high?
Schott Pharma AG KGaA's current Gross Profit is $369 Mil. Overall, Schott Pharma AG KGaA has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Gross Profit compare to ISRG and BDX?
Schott Pharma AG KGaA's Gross Profit of $369 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Schott Pharma AG KGaA and its competitors. Schott Pharma AG KGaA's current Gross Profit is $369 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Gross Profit of $369 Mil. The stock's GF Value™ is $5.35, compared to a current price of $4.37 — trading 18.3% below its estimated fair value. The current Gross Profit is $369 Mil. Schott Pharma AG KGaA's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Gross Profit is $369 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 18.3% below its estimated GF Value™ of $5.35.
Key valuation signals for SHTPY:
Gross Profit: $369 Mil
GF Value™: $5.35 vs. price of $4.37 (18.3% below fair value)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
69GF Score
Get the complete analysis for SHTPY
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
